You are here
Actinic Keratosis Treatment Market Overview 2019 | Global Industry Growth Rate, Size Estimation, Top Company Share, Regional Statistics By 2024
Global Actinic Keratosis Treatment Market: Information by Type (Medications and Procedures), End User (Hospitals & Oncology Centers, Dermatology Clinics and Ambulatory Surgical Center) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2023
Market Research Future published a cooked research report on “Global Actinic Keratosis Treatment Market Research Report - Forecast to 2024” Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2024.
Market Research Future (MRFR) has announced a new release on the global actinic keratosis market. The report studies the historical development and present status of the global actinic keratosis market in order to provide reliable forecasts regarding the probable growth trajectory of the market over the forecast period. According to the report, the global actinic keratosis market is expected to rise at a CAGR of 4% over the forecast period.
Actinic keratosis is a skin condition caused by repeated excessive exposure to solar radiation. It results in an area of skin becoming scaly or crusty. The development of actinic keratosis is linked to exposure to ultraviolet radiation from the sun, which causes abnormal proliferation of mutated keratinocytes situated in the lower layers of the epidermis. As a result, actinic keratosis manifests as a pre-cancerous condition that can develop into malignancies if left untreated. These lesions can appear on the face, neck, and arms, with middle-aged and elderly men who have been exposed to solar radiation continuously for a number of years appearing to be at the highest risk of the disease. People working with tar and coal are also likely to get actinic keratosis. Actinic keratosis can develop into squamous cell carcinoma if left untreated.
The increasing threat of cancer and the increasing efforts to wipe out cancer by developing stronger treatments are likely to drive the global actinic keratosis market over the forecast period. Cancer has emerged as a major challenge for the healthcare sector at present, with several types of cancer proving difficult to contain and exterminate. This is likely to mobilize support for the actinic keratosis market over the coming years.
Avail Free Sample Copy at https://www.marketresearchfuture.com/sample_request/2366
The global actinic keratosis market is segmented on the basis of medication, procedure, end user, and region.
By medication, the global actinic keratosis market is segmented into fluorouracil cream, imiquimod cream, ingenol mebutate gel, diclofenac gel, and others.
By procedure, the global actinic keratosis market is segmented into cryotherapy, photodynamic therapy, laser, chemical peels, and others. Cryotherapy is a commonly used treatment for actinic keratosis, while developing effective photodynamic therapy is likely to remain a key target for major players in the actinic keratosis market over the coming years.
Regionally, the global actinic keratosis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is dominated by North America and is likely to be the major regional segment of the global actinic keratosis market over the forecast period. The easy availability of advanced treatment procedures, including combination therapy as well as monotherapy, in North America is likely to be the major driver for the actinic keratosis market over the forecast period. The increasing efforts being taken on cancer research in North America are also likely to propel the actinic keratosis market over the forecast period, as actinic keratosis treatments play a vital role in preventing the formation of cancerous tumors and thus help reduce the burden on the healthcare sector created by the increasing prevalence of cancer.
Leading players in the global actinic keratosis market include Biofrontera AG, BioLineRx, Leo Pharma, 3M, Stanford Chemicals, Alma Lasers, Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, and Cipher Pharmaceuticals Inc.
In January 2019, Athenex Inc. and Chongqing Jingdong Junzhou Pharmaceuticals Co. Ltd. announced a partnership and licensing agreement for the development of KX2-391 for the treatment of actinic keratosis in China.
Browse Full Report @ https://www.marketresearchfuture.com/reports/actinic-keratosis-treatment-market-2366
Market Research Future
+1 646 845 9312
The reports of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.